A RETROSPECTIVE ANALYSIS OF SEQUENTIAL USE OF THE TYROSINE KINASE INHIBITORS (TKI) SORAFENIB (SOR) AND SUNITINIB (SUN) IN METASTATIC RENAL CELL CARCINOMA (mRCC)

被引：0
|
作者：
Calvani, N. [1 ,2 ]
Chetri, M. C. [1 ,2 ]
Cinefra, M. [1 ,2 ]
D'Amico, M. [1 ,2 ]
Fedele, P. [1 ,2 ]
Marino, M. [1 ,2 ]
Mazzoni, E. [1 ,2 ]
Nacci, A. [1 ,2 ]
Orlando, L. [1 ,2 ]
Rizzo, P. [1 ,2 ]
Schiavone, P. [1 ,2 ]
Sponziello, F. [1 ,2 ]
Cinieri, S. [1 ,2 ]
机构：
[1] A Perrino Hosp, Div Med Oncol, Brindisi, Italy
[2] A Perrino Hosp, Breast Unit, Brindisi, Italy
来源：
CANCER TREATMENT REVIEWS | 2010年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14
引用
收藏
页码：S99 / S99
页数：1
相关论文
共 50 条
  • [31] Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): Analysis for safety and activity on sunitinib progressive pts
    Sepulveda, J.
    Maroto, P.
    Andres, R.
    Diaz Padilla, I.
    Coronado, C.
    DelaRosa, F.
    Castellano, D. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Optimizing the Sequencial Treatment of Metastatic Renal Cell Carcinoma (MRCC) - a Retrospective, Multicenter, Analysis of 40 Patients Treated With Either Sorafenib, an mTOR Inhibitor (mTORI) and Sunitinib, or Sunitinib, an mTORI and Sorafenib
    Porta, C.
    Paglino, C.
    Procopio, G.
    Sabbatini, R.
    Bellmunt, J.
    Schmidingers, M.
    Bearz, A.
    Bamias, A.
    Melichar, B.
    Imarisio, I.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S514 - S514
  • [33] Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma
    Di Lorenzo, Giuseppe
    Buonerba, Carlo
    Federico, Piera
    Rescigno, Pasquale
    Milella, Michele
    Ortega, Cinzia
    Aieta, Michele
    D'Aniello, Carmine
    Longo, Nicola
    Felici, Alessandra
    Ruggeri, Enzo Maria
    Palmieri, Giovannella
    Imbimbo, Ciro
    Aglietta, Massimo
    De Placido, Sabino
    Mirone, Vincenzo
    EUROPEAN UROLOGY, 2010, 58 (06) : 906 - 911
  • [34] Re: Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma
    Di Lorenzo, Giuseppe
    Autorino, Riccardo
    JOURNAL OF UROLOGY, 2010, 183 (02): : 824 - 825
  • [35] Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study
    Loukas Kontovinis
    Konstantinos Laschos
    Alexandra Karadimou
    Charalambos Andreadis
    Aristotelis Bamias
    Panagiotis Paraskevopoulos
    Meletios Dimopoulos
    Konstantinos Papazisis
    Medical Oncology, 2012, 29 : 750 - 754
  • [36] Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study
    Kontovinis, Loukas
    Laschos, Konstantinos
    Karadimou, Alexandra
    Andreadis, Charalambos
    Bamias, Aristotelis
    Paraskevopoulos, Panagiotis
    Dimopoulos, Meletios
    Papazisis, Konstantinos
    MEDICAL ONCOLOGY, 2012, 29 (02) : 750 - 754
  • [37] Risk of primary progressive disease with tyrosine kinase inhibitors sorafenib and sunitinib in patients with renal cell carcinoma: A meta-analysis
    Su, X.
    Ranpura, V.
    Wu, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
    Keil, C.
    Goetze, L.
    Olbert, P.
    Hofmann, R.
    Nockher, W. A.
    Hegele, A.
    UROLOGE, 2015, 54 (06): : 811 - 818
  • [39] Sequential Therapy With Sorafenib and Sunitinib in Renal Cell Carcinoma
    Dudek, Arkadiusz Z.
    Zolnierek, Jakub
    Dham, Anu
    Lindgren, Bruce R.
    Szczylik, Cezary
    CANCER, 2009, 115 (01) : 61 - 67
  • [40] Sequential therapy with sorafenib and sunitinib in renal cell carcinoma
    Dham, A.
    Dudek, A. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345